For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

Semaglutide, more commonly known as Ozempic, can do more than help with weight loss. A new clinical trial shows it helps ...

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Atherosclerosis of the extracranial internal carotid artery (ICA) causes 10–20% of ischaemic strokes.1 As luminal stenosis of the ICA grows, the risk of ischaemic stroke increases,2 and removal of the ...

Semaglutide may relieve peripheral arterial disease experienced by many patients with type 2 diabetes, a new Montreal study ...

A new international study has found that semaglutide, a medication commonly used to treat type 2 diabetes and obesity, ...

A new study published in the journal of PLOS One showed that a decreased risk of peripheral artery disease (PAD) was linked to higher dietary vitamin E intake. Peripheral arterial disease is caused by ...

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes. (HealthDay News) — For patients with symptomatic peripheral ...

ELEVATED remnant cholesterol (RC) exerts a stronger independent causal effect on peripheral artery disease (PAD) than LDL cholesterol (LDL-C), with LDL-C’s impact largely dependent on coexisting RC ...

For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased walking distance.